-The worm that turned the tide on in vivo DART testing
-Virtual laboratories for non-animal disease research and toxicity testing
-Chipping away at in vivo nephrotoxicity testing
-Putting in vitro platforms at the heart of cardiotoxicity testing
-3D retinal organoids - a vision of the future
-Using microfluidics to eliminate surgical embryo transfer in mice
-Assessing the genotoxic potential of gene therapy products in vitro

-A.I. and Big Data - New Kids on the Toxicology Block
-Smart Chemistry - Algorithms for Chemical Classification and Clustering

-Pred-Skin: A Web Portal for Accurate Prediction of Human Skin Sensitizers
-Evaluation of the Global Performance of Eight In Silico Skin Sensitization Models
-Skin Sensitization In Silico Protocol

-Developmental NeuroToxicity (DNT)
-Evidence-based Toxicology Collaboration (EBTC)
-Good Cell Culture Practice (GCCP) Program
-Green Toxicology
-Cosmetic and TestSmart Program
-Education program
-Refinement Program
-World Congress on Alternatives
-Policy Program
-Future Perspectives

-Welcome and Introductions
-Reflections on 20 Years of ICCVAM
-ICCVAM Workgroup Updates
-NICEATM Update
-Update on FDA Activities on Alternative Methods
-IATA for Developmental Neurotoxicity
-Update on Alternatives Research Activities at EPA
-EPA Office of Pesticide Programs
-Update from EPA/OSCPP/OPPT
-USDA Animal Welfare Information Center
-59MDW Science and Technology Overview and Upcoming Toxicology Projects
-OSHA Update to ICCVAM
-NCATS Update on Tox21 Activities
-Measurement Science Activities Under ICCVAM
-OECD Test Guidelines Programme Update

-Welcome and Introductions
-NICEATM and NTP Update
-ICCVAM Workgroup Updates
-Consumer Product Safety Commission Guidance for Industry and Test Method Developers
-USDA Animal Welfare Information Center
-Application of NAMs, Surrogates, and Read-across in Rapid Development of PBPK Models for Human Health Risk Assessment
-Investigation of Parathion-induced Neurotoxicity in SHSY5Y Cells Demonstrates Utility of the Assay as an Alternative Animal Model
-Assessment of Acute Oral Toxicity for Mixtures Using In Silico Modeling Methods
-Alternative Approaches to Ecotoxicological Testing and Assessment
-Impact of Alternatives to Animals in VA Research
-Update on EPA ORD New Approach Method Research Activities
-Recent Progress Towards Reducing Animal Use & Adopting NAMs at EPA's Office of Pesticide Programs
-OPPT's Progress Implementing the Near-term Activities in the TSCA Strategic Plan
-Advancing Alternative Methods at FDA
-Measurement Science Activities Under ICCVAM
-OECD Test Guidelines Programme Update

-Coronavirus Research - Anything Goes?
-Animal Models and Alternatives for COVID-19 Research
-Research Response of the European Commission to Address the COVID-19 Pandemic

-COVID-19 – What is in the Box of Alternative Methods??
-Human Pluripotent Stem Cell Models for COVID-19 Disease Modeling and Drug Screening
-3Rs and COVID-19 Vaccine Development: Regulatory Aspects

-Organoids and Single Cell Analyses as Tools to Substitute Mouse Models in Cancer Research
-Pain management and assessment in mouse femoral fracture models
-BEHAVE: Developing a toolkit for deep-behavior profiling of laboratory rodents
-Fish cell lines and the 3Rs: fundamental developments and application in chemical risk assessment

-Supraglottic airway devices as a means of refining laboratory animal anaesthesia
-Development of a new in vitro metastasis assay
-An in vitro method to predict sudden adverse lung effects
-QSAR modeling of chemical substances’ possible interference with the thyroid hormone system

-A guideline for marking and tagging fish
-Let your digital twin become your own personalized guinea pig
-Developing a complex model of bone formation
-Reducing the use of animals for studying transmission of respiratory viruses

-Overview of EPA NAMs Work Plan
-Progress on Implementing the TSCA Alternatives Strategic Plan
-Using Chemical, Biological, and In Vivo Data for NAMs: Which data do we have, and what can we do with it?
-Transcriptome-Based Derivation of an In Vivo POD: Current and Future Utility
-Drugmonizome and Drugmonizome-ML: Integration and Abstraction of Small Molecule Attributes for Drug Set Enrichment Analysis and Machine Learning
-"Fit for Purpose" for Organotypic Models in Environmental Health Protection

-Retrofitting an Estrogen Receptor Transactivation Assay with Metabolic Competence
-In Vitro Disposition of Tox21 Chemicals: Initial Results and Next Steps
-An OECD Harmonized Template (OHT) to Report NAM Results in Regulatory Environments: Principles and Practical Use
-Case Study #1: Integration of NAM Data for Evaluating Potential Developmental Neurotoxicity
-Case Study #2: Integration of NAM Data in a Next Generation Risk Assessment for Cosmetic Ingredients
-Case Study #3: Incorporating the Threshold of Toxicological Concern into Regulatory Decisions under the Amended Toxic Substances Control Act

-Updates from Europe Part I: Programs advancing informed substitution
-Industry experience implementing alternatives assessment and substitution Part I: Lessons learned from large multi-nationals

-Updates from Europe Part II: Safe-By-Design
-Industry experience implementing alternatives assessment and substitution Part II: Lessons learned from small business users of chemicals

-Part I: Considering Uncertainty: Real-world strategies to make decisions
-Part II: Considering Trade-offs: Real-world strategies to make decisions(no video)

-Public Awareness Through Campaigns and Investigations
-Creating Awareness Amongst Regulators and Legislators

-What Role Can the Public Understanding of Science Play in Ending Animal Testing?
-REACH, current changes and their implications